Buy & Sell Fastly Inc (FSLY) – Fastly Inc Price Today
Aura AI Summary
Key Stats
- $4.94BMarket Cap
- TechnologySector
- -37.46%3M Drawdown
- $5.01BEnterprise Value
- -Dividend Yield
- 65% Buy | 35% SellTrading Activity
- 25 daysTypical Hold Time
Fastly Inc (FSLY) is currently valued at a market capitalization of $4.94B, with an enterprise value of $5.01B. Over the past 52 weeks, Fastly Inc has traded between a low of $6.03 and a high of $33.5, highlighting its annual price range. Over the past three months, Fastly Inc has recorded a drawdown of -37.46%, reflecting recent price volatility. On average, investors hold Fastly Inc for approximately 25 days, indicating typical investor behavior on the platform.
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Most Recent News
2026 ChicagoCISO ORBIE Awards honor top CISOs for leadership in enterprise security and business impact
The 2026 ChicagoCISO ORBIE Awards recognized leading chief information security officers (CISOs) from major companies like CNA Financial, Paychex, and Intermountain Health for their outstanding leadership in cybersecurity. The awards highlight CISOs ...
Ticketmaster cuts 8% of workforce despite Live Nation's strong Q1 ticket sales
Ticketmaster has laid off 350 employees, about 8% of its global staff, mainly in engineering, product, and design roles, shortly after Live Nation reported strong Q1 revenue of $3.79 billion, beating estimates. Despite this, Live Nation posted a Q1 o...
Over 25 pharma firms advance 30+ PARP inhibitors in clinical trials for cancer treatment.
More than 25 pharmaceutical companies are actively developing over 30 PARP inhibitor drugs, targeting cancers like breast, prostate, and solid tumors. These drugs work by blocking DNA repair in cancer cells, leading to cell death, especially in tumor...
